menu
    • menu
    [{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Phase II","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Ardelyx","highestDevelopmentStatusID":"8","companyTruncated":"Ardelyx \/ Ardelyx"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor Hydrochloride","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor Hydrochloride","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0.52000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.52000000000000002,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ardelyx \/ SLR Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ SLR Capital Partners"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ardelyx \/ Ardelyx","highestDevelopmentStatusID":"15","companyTruncated":"Ardelyx \/ Ardelyx"}]

    Find Clinical Drug Pipeline Developments & Deals by Ardelyx

    Menu

    Ardelyx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Recipient : Fosun Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)

                            Details : Wan Ti Le (tenapanor HCl) is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for treatment of chronic kidney disease.

                            Product Name : Wan Ti Le

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 26, 2025

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Recipient : Fosun Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphat...

                            Details : Xphozah (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), indicated for the treatment of pediatric Hyperphosphatemia.

                            Product Name : Xphozah

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 15, 2023

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : SLR Capital Partners

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Ad...

                            Details : The financing will support the commercialization of company's two FDA approved products, Ibsrela (tenapanor), for irritable bowel syndrome with constipation, and Xphozah (tenapanor), indicated to reduce serum phosphorus in adults with chronic kidney dise...

                            Product Name : Xphozah

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 17, 2023

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : SLR Capital Partners

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor

                            Details : Xphozah (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), indicated for the treatment in adult with chronic kidney disease o...

                            Product Name : Xphozah

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 17, 2023

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tenapanor for Hyperphosphatemia Approved in Japan

                            Details : Phozevel (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the NHE3, indicated for the treatment improvement of hyperphosphatemia in adult patients with CKD on dial...

                            Product Name : Phozevel

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 25, 2023

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Fosun Pharmaceutical

                            Deal Size : $125.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

                            Details : The agreement provides Fosun Pharma the rights to develop and commercialize Ardelyx's lead product, tenapanor, in China for the treatment of patients with irritable bowel syndrome with constipation and for the treatment of hyperphosphatemia related to ch...

                            Product Name : Xphozah

                            Product Type : Small molecule

                            Upfront Cash : $12.0 million

                            July 13, 2023

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Fosun Pharmaceutical

                            Deal Size : $125.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH ...

                            Details : Xphozah (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), indicated for the treatment in adult with chronic kidney disease o...

                            Product Name : Xphozah

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 17, 2023

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)

                            Details : Xphozah (tenapanor) is a first-in-class, phosphate absorption inhibitor that has a novel mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), indicated for the treatment in adult with chronic kidney disease o...

                            Product Name : Xphozah

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 18, 2023

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult P...

                            Details : Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials.

                            Product Name : Xphozah

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 16, 2022

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Ardelyx

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH®...

                            Details : XPHOZAH (tenapanor),is an investigational first-in-class phosphate absorption inhibitor, With its unique blocking MOA, XPHOZAH acts locally in gut, reducing phosphate absorption through paracellular pathway, primary pathway of phosphate absorption.

                            Product Name : Xphozah

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 03, 2022

                            Lead Product(s) : Tenapanor

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth